Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$145.82 USD
+7.24 (5.22%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $145.80 -0.02 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
INSP 145.82 +7.24(5.22%)
Will INSP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INSP
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
INSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
Three Reasons to Retain Inspire Medical (INSP) Stock for Now
Other News for INSP
Inspire Medical price target lowered by $63 at Truist, here's why
InspireSemi Announces Non-Brokered Private Placement of Units and Results of Annual General and Special Meeting
Inspire Medical Systems, Inc. to Report Second Quarter 2024 Financial Results on August 6, 2024
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX) and Inspire Medical Systems (INSP)
Inspire Medical Systems (INSP) Gets a Buy from Piper Sandler